← Leaderboards
Matthew R. Reynolds
University Of Wisconsin-Madison
$4,280,029
Attributed
$4,280,029
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $770.7K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,280,029 · 3
By mechanism
R01$3,956,622 · 2
R56$323,407 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Scott M Berry$6,162,635
- Nathan M Sherer$6,676,911
- Jeremy A Sullivan$686,140
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralCellsImmune ResponseMonkeysCd4 Positive T LymphocytesPreventMathematical ModelMacaca MulattaPersonsIn VitroAftercareAntiretroviral TherapyImmunologicsAntiviral ImmunityIn VivoDisease RemissionBar CodesEventClinically RelevantClinical TrialsInterruptionAutologousAffectCytotoxic T-Lymphocytes
Grant awards (7)
Determining the impact of ultra-small SIV reservoirs on sustained ART-free remission$742,442
R01 · FY2025 · AI · contact PI
Determining the impact of ultra-small SIV reservoirs on sustained ART-free remission$767,960
R01 · FY2024 · AI · contact PI
Determining the impact of ultra-small SIV reservoirs on sustained ART-free remission$447,305
R01 · FY2023 · AI · contact PI
Determining the impact of ultra-small SIV reservoirs on sustained ART-free remission$323,407
R56 · FY2023 · AI · contact PI
Alloimmunization as a novel prophylactic vaccine for AIDS viruses$665,913
R01 · FY2017 · AI · contact PI
Alloimmunization as a novel prophylactic vaccine for AIDS viruses$665,913
R01 · FY2016 · AI · contact PI
Alloimmunization as a novel prophylactic vaccine for AIDS viruses$667,089
R01 · FY2015 · AI · contact PI